01692nas a2200337   4500000000100000008004100001260001300042653001500055653001000070653002900080653001200109653002100121653001100142653001100153653003000164653001200194653000900206653001300215653001700228100001500245700001300260700001300273700001600286700001700302245005200319300001100371490000700382050003200389520091900421022001401340       1976                            d  c1976 Jul10aAdolescent10aAdult10aClinical Trials as Topic10aDapsone10aErythema Nodosum10aFemale10aHumans10aInjections, Intramuscular10aleprosy10aMale10aSulfones10aTime Factors1 aGanapati R1 aNaik S S1 aShah M H1 aShirsat L S1 aGaitonde B B00aClinical trial of DADDS in lepromatous leprosy.  a238-430 v48  aInfolep Library - available3 a<p>This presentation reports the results of a short clinical trial with DADDS in 23 patients of lepromatous leprosy. Injections of DADDS administered intramuscularly in a dose of 225 mg every 70 days produced clinical regression noticeable earliest at few week after the secondn injection. A fall in the morphological index from 5.0 to 0.6 was observed in patients who had received from 3 to 7 injections. Erythema nodosum leprosum was encountered in 7 cases, four of which had moderate to severe grades of reaction. It is advisible to discontinue further injection of DADDS if initial signs of ENL are noticed, which are likely to occur after the second injection. These ENL responded well to the usual line of antireaction treatment. DDS level in blood was found to be more than 10 ng/ml before the fresh administration of DADDS upto the seventh injection, representing the period of follow-up in this study.</p>  a0024-1024